News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN)'s Fluenz Tetra Gets European Marketing Grant


12/6/2013 8:18:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca Plc. (AZN: Quote,AZN.L), Friday said its nasally administered vaccine, Fluenz Tetra, got Marketing Authorisation from the European Commission. Fluenz Tetra is a four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age. Through this approval, the vaccine becomes the only intra-nasal four-strain influenza vaccine available in Europe.

Help employers find you! Check out all the jobs and post your resume.

Read at RTT News
Read at Reuters
Read at News Release
Read at Wall Street Journal


comments powered by Disqus
   
Influenza
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES